Communiqués Algernon Pharmaceuticals Inc.

Actions

AGN

CA01559R4008

Temps Différé Canadian Securities Exchange Autres places de cotation 17:42:25 05/07/2024			Varia. 5j.	Varia. 1 janv.
0,12 ^CAD	-4,00%		+4,35%	+84,62%

30/04	Algernon Pharmaceuticals Inc. annonce ses résultats pour le deuxième trimestre et les six mois terminés le 29 février 2024	CI
01/04	Algernon Pharmaceuticals ira de l'avant avec son programme de recherche sur le médicament psychédélique DMT pour les accidents vasculaires cérébraux comme principal actif	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Algernon Pharmaceuticals : Notice of Annual General Meeting of Shareholders	26/06	PU
Algernon Pharmaceuticals : Request for Financial Statements	26/06	PU
Algernon Pharmaceuticals : Voting Instruction Form	26/06	PU
Algernon Pharmaceuticals : Appointment of Proxyholder	26/06	PU
Algernon Pharmaceuticals : Information Circular	26/06	PU
Algernon Pharmaceuticals : Notice and Access Procedures for AGM	27/05	PU
Algernon Pharmaceuticals Engages ICP Securities Inc. for Automated Market Making Services	21/05	AQ
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 - 8th, 2024	25/04	AQ
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024	24/04	AQ
Algernon Pharmaceuticals CEO Christopher J. Moreau to Be Featured on Radius Research's Pitch, Deep Dive and Q&A Webinar on April 16th, 2024	11/04	AQ
Algernon Pharmaceuticals to Move Forward with Psychedelic Drug DMT Stroke Research Program as its Lead Asset	01/04	AQ
Algernon Pharmaceuticals Strikes Deal to Advance Ifenprodil in Chronic Cough Treatment	28/03	AQ
Canadian Investment Regulatory Organization Trade Resumption - AGN	27/03	AQ
Algernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position	27/03	AQ
Canadian Investment Regulatory Organization Trading Halt - AGN	27/03	AQ
Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat CKD	31/01	AQ
Algernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosis	11/01	AQ
Algernon Pharmaceuticals Announces Closing of Private Placement	27/12	AQ
Algernon Pharmaceuticals Announces Increase to Private Placement	27/12	AQ
Algernon Pharmaceuticals Announces Private Placement	13/12	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Algernon Pharmaceuticals Inc.

Actions

AGN

CA01559R4008

Communiqués

Filtres